CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that clinical data evaluating tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and ficlatuzumab (formerly AV-299), the company’s lead monoclonal antibody candidate, will be featured in five presentations at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2011 at McCormick Place in Chicago.
